Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study (Q46226201)

20 December 2017

title

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study (English)

1 reference

20 December 2017

author name string

T Rau

1

1 reference

20 December 2017

H Wuttke

2

1 reference

20 December 2017

L M Michels

3

1 reference

20 December 2017

U Werner

4

1 reference

20 December 2017

K Bergmann

5

1 reference

20 December 2017

M Kreft

6

1 reference

20 December 2017

M F Fromm

7

1 reference

20 December 2017

T Eschenhagen

8

1 reference

20 December 2017

language of work or name

English

0 references

publication date

26 November 2008

1 reference

20 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

20 December 2017

volume

85

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

page(s)

269-272

1 reference

20 December 2017

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Common Variants in Myocardial Ion Channel Genes Modify the QT Interval in the General Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

Oxidation phenotype--a major determinant of metoprolol metabolism and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

7 January 2021

Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

7 January 2021

Stereoselective disposition of carvedilol is determined by CYP2D6

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

7 January 2021

Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

7 January 2021

Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

7 January 2021

Association of the G(s)alpha gene with essential hypertension and response to beta-blockade

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.218

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.218

1 reference

20 December 2017

1 reference

20 December 2017